世界中医药2017，Vol.12Issue(5)：1072-1076,5.DOI:10.3969/j.issn.1673-7202.2017.05.031
丹红注射液与长春西汀联合治疗缺血性脑血管病的综合评价
Danhong Injection with Vinpocetine in Treating Ischemic Cerebrovascular Disease:A Comprehensive Evaluation
摘要
Abstract
Objective: To evaluate the Danhong combined with Vinpocetine for cerebrovascular diseases in terms of efficacy, safety and economy.Methods: A total of 11 articles were analyzed by meta-analysis and cost-effect method.Results: According to the inclusive and exclusive criteria, 10 articles (953 patients) were included.Meta-analysis showed that the treatment group had significant effect [OR=3.67, 95%CI (2.45, 5.51), P<0.00001], the NIHSS was improved [MD=-3.17, 95%CI (-4.89,-1.44),P<0.01] and the level of hs-CRP was reduced [MD=-1.57,95%CI (-2.92,-0.22),P<0.01] and IL-6 [MD=-1.11, 95%CI(-1.72,-0.49), P<0.01].There was no significant difference in the adverse reaction rate between the two groups [OR=0.62, 95%CI(0.24,1.63), P=0.33].The cost of the control group was lower than that of the treatment group (C/E=134.35~201.52,200.38~312.66).For each additional unit effect, the cost of the treatment group was higher (△C/△E=341.88~1 171.07).Conclusion: The effect of Danhong injection combined with Vinpocetine in the treatment is superior to that of the control group, without higher incidence of adverse reactions.From the economic point of view, the combination treatment has higher cost, suggesting that the clinical selection and medication plan should depend on patients′ reality and condition.关键词
丹红注射液/长春西汀/缺血性脑血管病/有效性/安全性/经济性Key words
Danhong Injection/Vinpocetine/Ischemic cerebrovascular disease/Efficacy/Safety/Economy分类
医药卫生引用本文复制引用
侯新,牟稷征,王丽霞..丹红注射液与长春西汀联合治疗缺血性脑血管病的综合评价[J].世界中医药,2017,12(5):1072-1076,5.基金项目
北京药学会临床药学研究项目 （）
